メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ

Metachronous lung cancer: indication and outcome

  • M. Chida
  • , T. Hasumi
  • , Y. Hoshikawa
  • , Y. Matsumura
  • , M. Sato
  • , M. Handa
  • , T. Kondo

研究成果: ジャーナルへの寄稿学術論文査読

抄録

Although lobectomy is the standard surgical treatment for primary lung cancer, it is unclear whether lobectomy will be benefit for patients with metachronous lung cancer. The purpose of this study is to evaluate the difference of benefit between lobectomy and limited resection at second lung resection. Forty-eight patients, who had already undergone lobectomy due to primary lung cancer, undergoing second lobectomy (n = 30) or limited resection (n = 18) for metachronous lung cancer were investigated. The over-all 5-year survival rate of second operation was 51.9%. Although there was no significant difference of 5-year survival rates between lobectomy and limited resection, 50.4% and 49.4%, respectively, lobectomy for T1N0 subset prolonged the survival compared to limited resection, 5-year survival rates, 69.6% and 31.7%, respectively. However, lobectomy resulted in more postoperative complications and less preservation of lung function. Lobectomy should be considered the surgical procedure of choice for patients with metachronous T1N0 lung cancer when lung function is preserved.

本文言語英語
ページ(範囲)41-44
ページ数4
ジャーナルKyobu geka. The Japanese journal of thoracic surgery
55
1
出版ステータス出版済み - 01-2002
外部発表はい

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

  1. SDG 3 - すべての人に健康と福祉を
    SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

  • 医学一般

フィンガープリント

「Metachronous lung cancer: indication and outcome」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル